Urogen Pharma Ltd (URGN)

$16.96 +1.50 (9.70%)
Market Cap 714.27M
Revenue (ttm) 90.40M
Net Income (ttm) -126.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -140.34%
Debt to Equity Ratio -2.63
Volume 2,119,000
Avg Vol 3,622,494
Day's Range N/A - N/A
Shares Out 46.20M
Stochastic %K 91%
Beta 1.02
Analysts Strong Sell
Price Target $34.38

Company Profile

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution design...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 768 9780
Address:
400 Alexander Park Drive, 4th Floor, Princeton, United States
b3akohe
b3akohe Jul. 23 at 12:45 PM
$URGN this is an absolute must own stock. 2 approved products, many in the pipeline as well. PT $50 extremely appetizing for a bigger pharmaceutical company to purchase. I see institutional ownership increasing. No brainer!!!
1 · Reply
prabhubalan
prabhubalan Jul. 23 at 11:42 AM
$URGN give me that 20$
0 · Reply
Mkemovic23
Mkemovic23 Jul. 23 at 4:43 AM
$URGN part 2 of his write up - $36 low end target, $57 top end. Thx for providing this
1 · Reply
Mkemovic23
Mkemovic23 Jul. 23 at 4:42 AM
$URGN this is a good write up on urgn valuation
0 · Reply
Main_Street_Risks
Main_Street_Risks Jul. 23 at 3:06 AM
$URGN what are some of your opinions on peak sales and what the valuation of the company should be for rest of 2025. What's a reasonable target?
1 · Reply
chickenboy
chickenboy Jul. 23 at 1:12 AM
$URGN I apologize if this has already been posted but for anyone that wants to get into the nitty-gritty on how Zusduri works and what real urologists think of it check out urologytimes.com. Very interesting takes, both pro and con, regarding the drug and hurdles it will face. GLTA.
0 · Reply
BioStick123
BioStick123 Jul. 22 at 11:30 PM
$APLS all of u should move to $URGN
0 · Reply
Mkemovic23
Mkemovic23 Jul. 22 at 10:41 PM
$URGN either testing 20.70 on this run or 24.13… the news supports the latter price to test
0 · Reply
spartan123
spartan123 Jul. 22 at 8:37 PM
$URGN Sofi screwed me so bad on some options prices I think they know something is up. Since they charged me at least double I should have at least twice as many calls. Brokers and MMs if you can't win just cheat.
0 · Reply
Mkemovic23
Mkemovic23 Jul. 22 at 8:36 PM
$URGN I don’t think it’s gonna take much to move this into the mid 20’s
0 · Reply
Latest News on URGN
UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Jul 21, 2025, 8:00 AM EDT - 2 days ago

UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Jul 7, 2025, 8:00 AM EDT - 16 days ago

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 28 Court Deadline (NASDAQ:URGN)

Jun 16, 2025, 8:17 AM EDT - 5 weeks ago

URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 28 Court Deadline (NASDAQ:URGN)

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen

Jun 15, 2025, 10:17 AM EDT - 5 weeks ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen

UroGen Pharma: Lessons Learned And Future Outlook

Jun 13, 2025, 1:05 PM EDT - 5 weeks ago

UroGen Pharma: Lessons Learned And Future Outlook

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen

Jun 12, 2025, 6:04 PM EDT - 5 weeks ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen

U.S. FDA Approves UroGen's ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

Jun 12, 2025, 1:28 PM EDT - 5 weeks ago

U.S. FDA Approves UroGen's ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

US FDA approves Urogen's bladder cancer drug

Jun 12, 2025, 12:48 PM EDT - 5 weeks ago

US FDA approves Urogen's bladder cancer drug

UroGen: Despite ODAC Vote, Hope Remains With Targeting Of Other  Cancer Subpopulation

Jun 10, 2025, 10:30 AM EDT - 6 weeks ago

UroGen: Despite ODAC Vote, Hope Remains With Targeting Of Other  Cancer Subpopulation

URGN LEGAL NOTICE: Lose Money when UroGen Pharma Ltd. Stock Plummeted 45%?

Jun 10, 2025, 8:47 AM EDT - 6 weeks ago

URGN LEGAL NOTICE: Lose Money when UroGen Pharma Ltd. Stock Plummeted 45%?

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 28, 2025 in UroGen Pharma Ltd. Lawsuit – URGN

Jun 9, 2025, 1:36 PM EDT - 6 weeks ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 28, 2025 in UroGen Pharma Ltd. Lawsuit – URGN

URGN INVESTOR NEWS: UroGen Pharma Ltd. has been Sued for Securities Fraud – Contact BFA Law before July 28 Deadline (NASDAQ:URGN)

Jun 8, 2025, 8:18 AM EDT - 6 weeks ago

URGN INVESTOR NEWS: UroGen Pharma Ltd. has been Sued for Securities Fraud – Contact BFA Law before July 28 Deadline (NASDAQ:URGN)

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 6, 2025, 8:00 AM EDT - 6 weeks ago

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Shareholders who lost money on UroGen Pharma Ltd. (NASDAQ: URGN) Should Contact Wolf Haldenstein

Jun 5, 2025, 9:31 AM EDT - 6 weeks ago

Shareholders who lost money on UroGen Pharma Ltd. (NASDAQ: URGN) Should Contact Wolf Haldenstein

URGN LAWSUIT: UroGen Pharma Ltd. Lawsuit Alleges Securities Fraud Violations - Investors Notified to Contact BFA Law

Jun 4, 2025, 3:46 PM EDT - 6 weeks ago

URGN LAWSUIT: UroGen Pharma Ltd. Lawsuit Alleges Securities Fraud Violations - Investors Notified to Contact BFA Law

URGN STOCK NOTICE: UroGen Pharma Ltd. Has Been Sued for Fraud; Investors Are Notified to Contact BFA Law Before July 28 Legal Deadline

Jun 3, 2025, 3:33 PM EDT - 7 weeks ago

URGN STOCK NOTICE: UroGen Pharma Ltd. Has Been Sued for Fraud; Investors Are Notified to Contact BFA Law Before July 28 Legal Deadline

Law Offices of Frank R. Cruz Encourages UroGen Pharma Ltd. (URGN) Investors To Inquire About Securities Fraud Class Action

Jun 3, 2025, 12:19 PM EDT - 7 weeks ago

Law Offices of Frank R. Cruz Encourages UroGen Pharma Ltd. (URGN) Investors To Inquire About Securities Fraud Class Action

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against UroGen Pharma Ltd. (URGN) And Encourages Shareholders to Reach Out

Jun 3, 2025, 10:00 AM EDT - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against UroGen Pharma Ltd. (URGN) And Encourages Shareholders to Reach Out

UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer

Jun 2, 2025, 11:00 AM EDT - 7 weeks ago

UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against UroGen Pharma Ltd. (URGN) and Encourages Shareholders to Learn More About the Investigation

Jun 2, 2025, 10:00 AM EDT - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against UroGen Pharma Ltd. (URGN) and Encourages Shareholders to Learn More About the Investigation

UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

Jun 2, 2025, 10:00 AM EDT - 7 weeks ago

UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 1, 2025, 10:00 AM EDT - 7 weeks ago

UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages UroGen Pharma Ltd. (URGN) Shareholders to Inquire about Securities Investigation

May 30, 2025, 10:00 AM EDT - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages UroGen Pharma Ltd. (URGN) Shareholders to Inquire about Securities Investigation

Law Offices of Howard G. Smith Encourages UroGen Pharma Ltd.

May 29, 2025, 3:00 PM EDT - 7 weeks ago

Law Offices of Howard G. Smith Encourages UroGen Pharma Ltd.

b3akohe
b3akohe Jul. 23 at 12:45 PM
$URGN this is an absolute must own stock. 2 approved products, many in the pipeline as well. PT $50 extremely appetizing for a bigger pharmaceutical company to purchase. I see institutional ownership increasing. No brainer!!!
1 · Reply
prabhubalan
prabhubalan Jul. 23 at 11:42 AM
$URGN give me that 20$
0 · Reply
Mkemovic23
Mkemovic23 Jul. 23 at 4:43 AM
$URGN part 2 of his write up - $36 low end target, $57 top end. Thx for providing this
1 · Reply
Mkemovic23
Mkemovic23 Jul. 23 at 4:42 AM
$URGN this is a good write up on urgn valuation
0 · Reply
Main_Street_Risks
Main_Street_Risks Jul. 23 at 3:06 AM
$URGN what are some of your opinions on peak sales and what the valuation of the company should be for rest of 2025. What's a reasonable target?
1 · Reply
chickenboy
chickenboy Jul. 23 at 1:12 AM
$URGN I apologize if this has already been posted but for anyone that wants to get into the nitty-gritty on how Zusduri works and what real urologists think of it check out urologytimes.com. Very interesting takes, both pro and con, regarding the drug and hurdles it will face. GLTA.
0 · Reply
BioStick123
BioStick123 Jul. 22 at 11:30 PM
$APLS all of u should move to $URGN
0 · Reply
Mkemovic23
Mkemovic23 Jul. 22 at 10:41 PM
$URGN either testing 20.70 on this run or 24.13… the news supports the latter price to test
0 · Reply
spartan123
spartan123 Jul. 22 at 8:37 PM
$URGN Sofi screwed me so bad on some options prices I think they know something is up. Since they charged me at least double I should have at least twice as many calls. Brokers and MMs if you can't win just cheat.
0 · Reply
Mkemovic23
Mkemovic23 Jul. 22 at 8:36 PM
$URGN I don’t think it’s gonna take much to move this into the mid 20’s
0 · Reply
oldpoorboy
oldpoorboy Jul. 22 at 8:25 PM
$URGN I even contacted a law firm requesting for assistance. But choose not to proceed on the same day.
0 · Reply
BioStick123
BioStick123 Jul. 22 at 8:05 PM
$URGN Will Goldman revise its baby target?
1 · Reply
Gros_gerrard
Gros_gerrard Jul. 22 at 8:01 PM
$URGN whataday !!!!
0 · Reply
outlawinvestor1
outlawinvestor1 Jul. 22 at 7:36 PM
$URGN delayed market response to 5 year durability data?
1 · Reply
ybk1234
ybk1234 Jul. 22 at 7:36 PM
$URGN 18$ bald
1 · Reply
WAJeff
WAJeff Jul. 22 at 7:33 PM
$URGN $17 52 week high
0 · Reply
lukasgx
lukasgx Jul. 22 at 7:31 PM
$URGN Fly me to the moon let me play among the stars…..⭐️🥰🥳
0 · Reply
lukasgx
lukasgx Jul. 22 at 7:30 PM
$URGN @mimiwor don’t see anymore….i guess you sold
1 · Reply
Mkemovic23
Mkemovic23 Jul. 22 at 7:28 PM
$URGN that was a major sell off and snap-back. Let’s close nhod. They are setting this company up for sale with patent protection out to 2041!
1 · Reply
TraderJoe65
TraderJoe65 Jul. 22 at 7:21 PM
$REPL This reminds me too much of $URGN , parallels in stock price and study results and then the turnaround. The same outcome would be great.
0 · Reply
Mkemovic23
Mkemovic23 Jul. 22 at 6:51 PM
$URGN NFA, just don’t sell!
1 · Reply
cmartin0528
cmartin0528 Jul. 22 at 6:47 PM
$URGN one of the best swing plays in my portfolio, bring on the 20’s, 30’s, and more!! Long…
0 · Reply